AU2022261265A1 - Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells - Google Patents
Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells Download PDFInfo
- Publication number
- AU2022261265A1 AU2022261265A1 AU2022261265A AU2022261265A AU2022261265A1 AU 2022261265 A1 AU2022261265 A1 AU 2022261265A1 AU 2022261265 A AU2022261265 A AU 2022261265A AU 2022261265 A AU2022261265 A AU 2022261265A AU 2022261265 A1 AU2022261265 A1 AU 2022261265A1
- Authority
- AU
- Australia
- Prior art keywords
- cpmb
- conjugate
- linker
- cyclic peptide
- fam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/089305 | 2021-04-23 | ||
| CN2021089305 | 2021-04-23 | ||
| PCT/CN2022/088117 WO2022222986A1 (en) | 2021-04-23 | 2022-04-21 | Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022261265A1 true AU2022261265A1 (en) | 2023-11-09 |
| AU2022261265A9 AU2022261265A9 (en) | 2023-11-16 |
Family
ID=83723528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022261265A Pending AU2022261265A1 (en) | 2021-04-23 | 2022-04-21 | Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240218023A1 (https=) |
| EP (1) | EP4326744A1 (https=) |
| JP (1) | JP2024516613A (https=) |
| KR (1) | KR20240044385A (https=) |
| CN (1) | CN117529490A (https=) |
| AU (1) | AU2022261265A1 (https=) |
| IL (1) | IL307882A (https=) |
| WO (1) | WO2022222986A1 (https=) |
| ZA (1) | ZA202309922B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024117938A1 (ru) * | 2022-11-30 | 2024-06-06 | Общество с ограниченной ответственностью "СИСТЕМА-БИОТЕХ" | Способы получения биоконъюгатов для печень-специфической направленной модуляции протеома |
| WO2024152775A1 (zh) * | 2023-01-17 | 2024-07-25 | 云合智药（苏州）生物科技有限公司 | 缀合物、配体单元及其用途 |
| TW202517784A (zh) * | 2023-07-14 | 2025-05-01 | 大陸商云合智藥（蘇州）生物科技有限公司 | 用於抑制己酮糖激酶表達的ＲＮＡｉ劑及其應用 |
| CN120040554B (zh) * | 2025-04-25 | 2025-07-18 | 云合智药（苏州）生物科技有限公司 | 环肽类肝靶向化合物、药物组合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| US11987647B2 (en) * | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
-
2022
- 2022-04-21 US US18/556,040 patent/US20240218023A1/en active Pending
- 2022-04-21 EP EP22791092.4A patent/EP4326744A1/en active Pending
- 2022-04-21 AU AU2022261265A patent/AU2022261265A1/en active Pending
- 2022-04-21 IL IL307882A patent/IL307882A/en unknown
- 2022-04-21 CN CN202280043909.8A patent/CN117529490A/zh active Pending
- 2022-04-21 JP JP2023564508A patent/JP2024516613A/ja active Pending
- 2022-04-21 KR KR1020237040193A patent/KR20240044385A/ko active Pending
- 2022-04-21 WO PCT/CN2022/088117 patent/WO2022222986A1/en not_active Ceased
-
2023
- 2023-10-24 ZA ZA2023/09922A patent/ZA202309922B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117529490A (zh) | 2024-02-06 |
| JP2024516613A (ja) | 2024-04-16 |
| ZA202309922B (en) | 2025-05-28 |
| EP4326744A1 (en) | 2024-02-28 |
| IL307882A (en) | 2023-12-01 |
| US20240218023A1 (en) | 2024-07-04 |
| AU2022261265A9 (en) | 2023-11-16 |
| WO2022222986A1 (en) | 2022-10-27 |
| KR20240044385A (ko) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022222986A1 (en) | Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells | |
| US12274752B2 (en) | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | |
| US11603532B2 (en) | Oligonucleotide compositions and methods of use thereof | |
| TWI750712B (zh) | 一種新化合物及其用途 | |
| US20230076803A1 (en) | Compound and drug conjugate, and preparation method and use thereof | |
| JP2022533722A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| JP2022534069A (ja) | 核酸、薬物組成物及び複合体並びに調製方法と使用 | |
| JP2025063139A (ja) | リンカー | |
| KR20160035081A (ko) | 생체 내에서 RNAi 유발제를 종양 세포로 전달하기 위한 폴리콘주게이트 | |
| JP2022533419A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| JP2022533421A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| EP4380624A1 (en) | Multivalent ligand clusters with diamine scaffold for targeted delivery of therapeutic agents | |
| EP4499830A1 (en) | Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents | |
| BR112020015071A2 (pt) | Conjugados de anticorpos liberáveis | |
| JP2025514805A (ja) | 化合物及び使用 | |
| US20190029997A1 (en) | Small molecular lung-targeting drug | |
| RU2828679C2 (ru) | Нуклеиновая кислота, фармацевтическая композиция, конъюгат, способ получения и применение | |
| WO2026067447A1 (en) | Small Interfering RNAs Targeting ANT2 and Uses Thereof for Disease Treatment | |
| WO2025261376A1 (zh) | 肝外递送配体及其缀合物 | |
| JP2025527979A (ja) | ３クラスターガラクトース系化合物、コンジュゲート、その調製方法、及び使用 | |
| CN119462821A (zh) | 新型GalNAc的靶向递送片段及其制备和应用 | |
| WO2025201467A1 (zh) | 用于抑制中枢神经系统靶基因表达的多肽寡核苷酸缀合物及其应用 | |
| HK40069355B (zh) | 化合物、缀合物及其用途 | |
| HK40024941A (en) | Novel compound and application thereof | |
| AU2024354107A1 (en) | Sirna inhibiting expression of amyloid precursor protein (app) gene, drug, and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |